Atlas Trials

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

Clinical trial NCT07204418 · RECRUITING

Trial details

NCT number
NCT07204418
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy Volunteers
Start date
2025-10-13
Primary completion
2026-12-03
Enrollment
56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.